Privo Technologies

PRV111 is a derivative of the PRV platform, a novel nanotechnology-based system that is capable of improving the efficacy of potent anticancer drugs and significantly improving their safety through topical treatment. This product has broad applications for use in most mucosal and skin cancers. PRV211 delivers highly potent cisplatin nanoparticles directly to the resected tumor bed, providing long lasting sustained release of the cytotoxic drug, aimed at eliminating tumor recurrence and micrometastases. PRV111 is a therapeutic patch used on several mucosal and dermal cancers. PRV111 consists of a unique polymeric mesh containing powerful chemotherapy-loaded nanoparticles and works by delivering the nanoparticles directly onto the tumor and regional lymph nodes. We strive to develop innovative therapeutics, to eliminate cancers, and prevent recurrence. We aim to provide better and more accessible treatment options to diverse patient populations around the world. The PRV™ platform enables targeted therapy while avoiding systemic toxicity to provide a safer, less invasive alternative to currently available treatments The PRV™ system is available in multiple dosage forms.